Evidence map›Paper›PMID 28332354›Full record

ArticleYonsei medical journal2017

Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.

Bo Mi Park, Eun Jin Kim, Hee Jin Nam, Dongdong Zhang, Chu Hyun Bae, Myeongmo Kang, Heeyoun Kim, Weontae Lee, Bjarne Bogen, Sung Kil Lim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonsei medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in immunology · 2024
    Article
  3. Article
  4. Drug Discovery of DKK1 Inhibitors.Frontiers in pharmacology · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Non-Viral Delivery System and Targeted Bone Disease Therapy.International journal of molecular sciences · 2019
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Bo Mi ParkBrain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea.
Eun Jin KimInstitute of Biomedical Sciences, Yonsei University, Seoul, Korea.
Hee Jin NamDivision of Endocrinology and Endocrine Research Institute, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Dongdong ZhangBrain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea.
Chu Hyun BaeBrain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea.
Myeongmo KangInstitute of Biomedical Sciences, Yonsei University, Seoul, Korea.
Heeyoun KimDepartment of Biochemistry, Yonsei University, Seoul, Korea.
Weontae LeeDepartment of Biochemistry, Yonsei University, Seoul, Korea.
Bjarne BogenCentre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Sung Kil LimBrain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea.
Yonsei University · KRUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDickkopf 1 (DKK1) has been extensively investigated in mouse models of multiple myeloma, which results in osteolytic bone lesions. Elevated DKK1 levels in bone marrow plasma and serum inhibit the differentiation of osteoblast precursors. Present pharmaceutical approaches to target bone lesions are limited to antiresorptive agents. In this study, we developed a cyclized oligopeptide against DKK1-low density lipoprotein receptor-related protein (LRP) 5/6 interaction and tested the effects of the oligopeptide on tumor burden. MATERIALS AND

methodsA cyclized oligopeptide based on DKK1-LRP5/6 interactions was synthesized chemically, and its nuclear magnetic resonance structure was assessed. Luciferase reporter assay and mRNA expressions of osteoblast markers were evaluated after oligopeptide treatment. MOPC315.BM.Luc cells were injected into the tail vein of mice, after which cyclized oligopeptide was delivered subcutaneously 6 days a week for 4 weeks.

resultsThe cyclized oligopeptide containing NXI motif bound to the E1 domain of LRP5/6 effectively on surface plasmon resonance analysis. It abrogated the Wnt-β-catenin signaling inhibited by DKK1, but not by sclerostin, dose dependently. RT-PCR and alkaline phosphatase staining showed increased expressions of osteoblast markers according to the treatment concentrations. Bioluminescence images showed that the treatment of cyclized oligopeptide reduced tumor burden more in oligopeptide treated group than in the vehicle group.

conclusionThe cyclized oligopeptide reported here may be another option for the treatment of tumor burden in multiple myeloma.

Indexed as

Animalsbeta CateninBone MarrowCell DifferentiationCell Line, TumorDisease Models, AnimalIntercellular Signaling Peptides and ProteinsMiceMultiple MyelomaOligopeptidesOsteoblastsSignal TransductionTumor BurdenWnt Proteinsbeta CateninDkk1 protein, mouseIntercellular Signaling Peptides and ProteinsOligopeptidesWnt ProteinsburdenDKK1Multiple myelomaoligopeptidetumorWnt signaling

Identifiers

PMID28332354
PMCPMC5368134
OpenAlexW2600832140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.